Karen Miotto

Dr. Karen Miotto


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2001 in The American Journal on Addictions
Verified
Journal Article
Closed access
PDF file
KMKaren Miotto
Karen Miotto
JDJack Darakjian
Jack Darakjian
JBJanice Basch
Janice Basch
SMShanna Murray
Shanna Murray
JZJennifer Zogg
Jennifer Zogg
RRRichard Rawson
Richard Rawson
Gamma‐hydroxybutyric acid (GHB) is gaining popularity as a drug of abuse. Reports of toxicity and lethality associated with GHB use have increased. This survey study was designed to identify patterns of GHB use, its effects, and withdrawal syndrome. A survey inquiring about the effects of GHB was administered to 42 users. The results showed that GHB was used to increased feelings of euphoria, relaxation, and sexuality. Adverse effects occurred more frequently in daily users and polydrug users than in occasional GHB users. Loss of consciousness was reported by 66% overdose by 28%% and amnesia by 13% of participants during GHB use and by 45% after GHB use. Three daily users developed a withdrawal syndrome that presented with anxiety, agitation, tremor, and delirium. Participants described GHB intoxication as having similarities to sedative‐hypnotic or alcohol intoxication. Regular use has been shown to produce tolerance and dependence. Participants dependent on GHB reported using multiple daily doses around the clock. High frequency users appeared at the greatest risk for developing withdrawal delirium and psychosis after abrupt discontinuation of GHB use.

1 September 2013 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
KMKaren Miotto
Karen Miotto
JSJoan Striebel
Joan Striebel
ACArthur K. Cho
Arthur K. Cho
CWChristine Wang
Christine Wang

1 April 2002 in The American Journal on Addictions
Verified
Journal Article
Closed access
PDF file
KMKaren Miotto
Karen Miotto
MMMichael McCann
Michael McCann
JBJanice Basch
Janice Basch
RRRichard Rawson
Richard Rawson
WLWalter Ling
Walter Ling
Naltrexone is an opiate antagonist used as a pharmacologic adjuvant for the treatment of opiate and alcohol addiction. It has been hypothesized that naltrexone blocks the stress‐response and well‐being effects associated with opioid peptides. This raises the clinical concern that naltrexone may cause dysphoria. The authors reviewed pharmacological and clinical data in alcohol, opioid, and nicotine studies to determine if an association between naltrexone and dysphoria exists. These studies did not reveal dysphoria to be a serious side effect produced by naltrexone treatment. Additional studies to evaluate long‐term endocrine effects and antidepressant combination therapy are warranted.

12 May 2020 in Academic Psychiatry
Verified
Journal Article
Open access
PDF file
RRRuby Romero
Ruby Romero
KMKaren Miotto
Karen Miotto
ACAlejandra Casillas
Alejandra Casillas
JSJesse Sanford
Jesse Sanford

1 August 2020 in Psychological Trauma: Theory, Research, Practice, and Policy
Verified
Journal Article
Closed access
KMKaren Miotto
Karen Miotto
JSJesse Sanford
Jesse Sanford
MBMelissa J. Brymer
Melissa J. Brymer
BBBrenda Bursch
Brenda Bursch
RPRobert S. Pynoos
Robert S. Pynoos
Institutions across the world are working to develop initiatives aimed at supporting the well-being of healthcare workers (HCWs) facing the psychological impacts of the novel coronavirus (COVID-19) pandemic. This Commentary identifies risks that HCWs are experiencing, reviews sources of fear and stress, and describes the implementation of a three-tiered model for the provision of emotional support and mental health services for clinical and nonclinical HCWs. The model recognizes the fluid, ever-evolving nature of the COVID-19 pandemic and includes proactive, visible, and easy-to-access supportive psychological services that expand the safety net and help address immediate and future mental health challenges of HCWs. (PsycInfo Database Record (c) 2020 APA, all rights reserved).

1 March 2012 in Journal of Addiction Medicine
Verified
Journal Article
Closed access
KMKaren Miotto
Karen Miotto
MHMaureen Hillhouse
Maureen Hillhouse
RDRoger Donovick
Roger Donovick
JCJerry Ba Cunningham-Rathner
Jerry Ba Cunningham-Rathner
CCCharlie Charuvastra
Charlie Charuvastra
WLWalter Ling
Walter Ling
Although use of buprenorphine in the treatment of opioid dependence is expected to continue to increase, little is known about the optimal setting for providing the medical and psychosocial care required with buprenorphine pharmacotherapy. Objective: This study compared buprenorphine therapy delivered in 3 distinct treatment settings: an opioid treatment program (OTP) offering individual counseling, a group counseling program utilizing the manualized Matrix Model (MMM) of cognitive-behavioral treatment, and a private clinic setting mirroring standard medical management for buprenorphine treatment provided specifically at a psychiatrist's private practice (primary care setting). Method: Participants were inducted on buprenorphine and provided with treatment over a 52-week study duration. All participants were scheduled for weekly treatment visits for the first 6 study weeks and 2 sites reduced treatment to monthly visits for dispensing of medication and psychosocial counseling. Outcomes include opioid use, participant retention in treatment, and treatment participation. Results: Participants presenting for treatment at the sites differed only by race/ethnicity and opioid use did not differ by site. Retention differed by treatment site, with the number of participants who stayed in the study until the end of 20 weeks significantly associated with treatment site. The mean number of minutes spent in each individual counseling session also differed by site. Although no difference in opioid use by treatment site was found, results document a significant association between opioid use and buprenorphine dose. Discussion: These results show some differences by treatment site, although the similarity and relative ease in which the sites were able to recruit participants for treatment with buprenorphine, and minor implementation problems reported suggests the feasibility of treatment with buprenorphine across various treatment settings. Conclusion: Similar rates of continued opioid use across study sites and few qualitative reports of problems indicates that treatment with buprenorphine and associated psychosocial counseling are safe and relatively easy to implement in a variety of treatment settings.